OsteoBiol ®

Case Reports

Publications

Videos

Tissue origin :
Cortico-cancellous heterologous bone mix
Tissue collagen :
Preserved
Physical form :
Slightly radiopaque granules
Composition :
100% granulated mix
Granulometry :
250-1000 µm
1000-2000 µm
Re-entry time :
4/5 months, depending on grafting site characteristics
Packaging :
Vial: 0.25 g, 0.5 g, 1.0 g, 2.0 g
Product codes :
250-1000 µm
M1052FS | 1 Vial | 0.25 g | Porcine
M1052FE | 1 Vial | 0.25 g | Equine
M1005FS | 1 Vial | 0.5 g | Porcine
M1005FE | 1 Vial | 0.5 g | Equine
M1010FS | 1 Vial | 1.0 g | Porcine
M1010FE | 1 Vial | 1.0 g | Equine
M1020FS | 1 Vial | 2.0 g | Porcine
M1020FE | 1 Vial | 2.0 g | Equine
1000-2000 µm
M0210FS | 1 Vial | 1.0 g | Porcine
M0220FS | 1 Vial | 2.0 g | Porcine
GMDN code : 46425

Characteristics: A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures⁽¹⁾ (matrix and porous form) and presents highly osteoconductive properties^(2,3).
It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.
Gen-Os® is gradually resorbable and provides support in bone neoformation helping to preserve the original graft shape and volume⁽⁴⁾. Moreover, thanks to its collagen content, the product facilitates blood clotting and the subsequent invasion of repairing and regenerative cells, favouring restitutio ad integrum of missing bone. Gen-Os® has proven to have marked hydrophilia⁽⁵⁾, and it is ideal to mix with GFs⁽⁶⁾.
Handling: Gen-Os® must always be hydrated and thoroughly mixed with either a few drops of sterile physiological solution (or patient's blood) to activate its collagen matrix and to enhance its adhesivity or with TSV Gel to increase graft stability in not self-contained defects. If necessary, it can as well be mixed with the drug selected for surgery.
Clinical information: Gen-Os®, a cortico-cancellous bone mix, has been the first product developed with the Tecnoss® innovative biotechnology and, due to its universal use, still is today the most demanded from the market. Gen-Os® has been successfully used and documented for alveolar ridge preservation⁽⁷⁾ in combination with Evolution membranes: the application of this biomaterial limits the alveolar ridge width reduction that would naturally occur with spontaneous healing, preserving thus the alveolar ridge volume and allowing a correct second stage implant placement⁽⁸⁾.
Gen-Os® has been used for lateral access maxillary sinus lift⁽³⁾ and dehiscence regeneration⁽⁹⁾, always in association with Evolution membranes.
Gen-Os® has been documented in periodontal regeneration of deep infrabony defects⁽¹⁰⁾. Due to its collagen content, once hydrated Gen-Os® becomes very sticky and hydrophilic⁽⁵⁾: it combines therefore extremely well with blood and is very stable once applied into the grafting site. Its cortico-cancellous composition allows a progressive resorption of osteoclastic type, with in parallel a similar rate of new bone formation⁽²⁾: these unique properties allow a very good graft volume preservation, a healthy and well vascularized new bony tissue and, ultimately, a successful implant rehabilitation. Gen-Os® is in fact able to boost vascularization: in vitro⁽¹¹⁾ assays proved an increase in the secretion of VEGF by periodontal ligament cells (PDL) in the presence of Gen-Os®, as well as an enhanced proliferation of endothelial cells.
Bibliography: ¹ FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA F, JUDAS F, FIGUEIREDO H
PHYSICOCHEMICAL CHARACTERIZATION OF BIOMATERIALS COMMONLY USED IN DENTISTRY AS BONE SUBSTITUTES - COMPARISON WITH HUMAN BONE
J BIOMED MATER RES B APPL BIOMATER, 2010 FEB; 92(2):409-19

² NANNMARK U, SENNERBY L
THE BONE TISSUE RESPONSES TO PREHYDRATED AND COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLIN IMPLANT DENT RELAT RES, 2008 DEC;10(4):264-70

³ CASSETTA M, PERROTTI V, CALASSO S, PIATTELLI A, SINJARI B, IEZZI G
BONE FORMATION IN SINUS AUGMENTATION PROCEDURES USING AUTOLOGOUS BONE, PORCINE BONE, AND A 50 : 50 MIXTURE: A HUMAN CLINICAL AND HISTOLOGICAL EVALUATION AT 2 MONTHS
CLIN ORAL IMPLANTS RES, 2015 OCT;26(10):1180-4

⁴ CARDAROPOLI D, CARDAROPOLI G
PRESERVATION OF THE POSTEXTRACTION ALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC STUDY
INT J PERIODONTICS RESTORATIVE DENT, 2008 OCT; 28(5):469-77

⁵FIGUEIREDO A, COIMBRA P, CABRITA A, GUERRA F, FIGUEIREDO M
COMPARISON OF A XENOGENEIC AND AN ALLOPLASTIC MATERIAL USED IN DENTAL IMPLANTS IN TERMS OF PHYSICO-CHEMICAL CHARACTERISTICS AND IN VIVO INFLAMMATORY RESPONSE
MATER SCI ENG C MATER BIOL APPL, 2013 AUG 1;33(6):3506-13

⁶ MIJIRITSKY E, FERRONI L, GARDIN C, BRESSAN E, ZANETTE G, PIATTELLI A, ZAVAN B
PORCINE BONE SCAFFOLDS ADSORB GROWTH FACTORS SECRETED BY MSCS AND IMPROVE BONE TISSUE REPAIR
MATERIALS, 2017 SEP 8;10(9)

⁷ CHECCHI V, FELICE P, ZUCCHELLI G, BARAUSSE C, PIATTELLI M, PISTILLI R, GRANDI G, ESPOSITO M
WIDE DIAMETER IMMEDIATE POST-EXTRACTIVE IMPLANTS VS DELAYED PLACEMENT OF NORMAL-DIAMETER IMPLANTS IN PRESERVED SOCKETS IN THE MOLAR REGION: 1-YEAR POST-LOADING OUTCOME OF A RANDOMISED CONTROLLED TRIAL
EUR J ORAL IMPLANTOL, 2017;10(3):263-278

⁸ FESTA VM, ADDABBO F, LAINO L, FEMIANO F, RULLO
PORCINE-DERIVED XENOGRAFT COMBINED WITH A SOFT CORTICAL MEMBRANE VERSUS EXTRACTION ALONE FOR IMPLANT SITE DEVELOPMENT: A CLINICAL STUDY IN HUMANS CLIN IMPLANT DENT RELAT RES, 2013 OCT;15(5):707-13

⁹ CASSETTA M, RICCI L, IEZZI G, DELL'AQUILA D, PIATTELLI A, PERROTTI V
RESONANCE FREQUENCY ANALYSIS OF IMPLANTS INSERTED WITH A SIMULTANEOUS GRAFTING PROCEDURE: A 5-YEAR FOLLOW-UP STUDY IN MAN
INT J PERIODONTICS RESTORATIVE DENT, 2012 OCT;32(5):581-9

¹⁰ ESPOSITO M, GRUSOVIN MG, LAMBERT F, MATOS S, PIETRUSKA M, ROSSI R, SALHI L, BUTI J
THE EFFECTIVENESS OF A RESORBABLE BONE SUBSTITUTE WITH A RESORBABLE MEMBRANE IN THE TREATMENT OF PERIODONTAL INFRABONY DEFECT - A MULTICENTER RANDOMISED CONTROLLED TRIA
EUR J ORAL IMPLANTOL, 2015;8(3):233-244

¹¹ ROMBOUTS C, JEANNEAU C, CAMILLERI J, LAURENT P, ABOUT I
CHARACTERIZATION AND ANGIOGENIC POTENTIAL OF XENOGENEIC BONE GRAFTING MATERIALS: ROLE OF PERIODONTAL LIGAMENT CELLS
DENT MATER J, 2016 DEC 1;35(6):900-907

Gen-Os®